US-based CoLucid Pharmaceuticals has initiated the first Phase III trial (SAMURAI) of its lead product candidate, lasmiditan, for the acute treatment of migraine headaches in adults.

Lasmiditan is designed to deliver efficacy for the acute treatment of migraine headaches in adults without the vasoconstrictor activity associated with previous generations of migraine therapies.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

SAMURAI is designed to evaluate the safety and efficacy of lasmiditan 100mg and 200mg in comparison to placebo two hours after dosing on freedom from migraine headache pain, which is the primary endpoint, and on freedom from the most bothersome associated symptom of migraine, which is the secondary endpoint.

A total of 1,483 migraine patients will be treated with lasmiditan in the randomised, double-blind, placebo-controlled parallel group trial at around 70 US sites for about 12 months.

The company expects to include patients with migraine and those who also have cardiovascular risk factors or cardiovascular disease.

See Also:

The Phase III trial is being conducted under a Special Protocol Assessment agreement with the US Food and Drug Administration (FDA).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway and it has been given the generic stem name ‘ditan’, which distinguishes it from other drug classes, including triptans, the current standard of care for migraine.

The company has already completed seven clinical trial for lasmiditan, including a thorough QTc study and a Phase IIb trial evaluating lasmiditan as a treatment for a single migraine attack in 391 patients.

Lasmiditan is designed for patients who are poorly served by the existing therapies, including patients with cardiovascular risk factors or cardiovascular disease who may not be able to take triptans.